MENU
MYO
Stock ticker: ASE
PRICE
CHANGE
CAPITALIZATION

Myomo (MYO) Earnings Date & Reports

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders... Show more

A.I. Advisor
published Earnings

MYO is expected to report earnings to fall 2.86% to -6 cents per share on March 10

Myomo MYO Stock Earnings Reports
Q4'26
Est.
$-0.07
Q3'26
Beat
by $0.01
Q2'26
Beat
by $0.01
Q1'26
Beat
by $0.05
Q4'25
Missed
by $0.01
The last earnings report on November 09 showed earnings per share of -7 cents, beating the estimate of -7 cents. With 381.82K shares outstanding, the current market capitalization sits at 47.93M.
A.I.Advisor
Nov 10, 2026

Myomo (MYO) Q3 2026 Earnings Recap: What Record Orders Signal for the Year Ahead

Key Takeaways

  • Myomo reported third-quarter 2026 revenue of $12.33 million, up about 22% from $10.09 million a year earlier and above the consensus estimate of roughly $11.5 million.
  • Gross margin expanded to 71.3%, up from 63.8% in the prior-year quarter, helped by a higher average selling price and lower material costs.
  • The company reached adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) break-even, compared with a loss of $2.7 million a year ago.
  • Net loss was $4.2 million, or $0.10 per share, which included a non-cash charge of about $1.8 million tied to the valuation of derivative liabilities.
  • Management narrowed its full-year 2026 revenue guidance to $46 million to $47 million, at the upper end of its prior $45 million to $47 million range.
  • For more detail on this ticker, you can review Major News, Today's Price Move, Price Targets, and Forecast.
  • You can also explore Trending AI Robots to see AI-driven strategies currently drawing trader interest.

Earnings Context and Why It Matters

Myomo, a wearable medical robotics company, develops and markets the MyoPro product line, a powered upper-limb orthosis (brace) that uses the patient's own EMG (electromyography) signals to restore arm and hand function for people with neurological disorders and upper-limb paralysis. The third-quarter report matters because it tests whether the company's push toward scale and operating leverage is translating into a clear path to profitability. Investors have been watching revenue growth, gross margin, cash burn, and the MyoConnect referral program, all of which signal how efficiently Myomo is converting demand into revenue while controlling costs.

Reported Results

For the third quarter ended September 30, 2026, Myomo posted revenue of $12.33 million, a year-over-year increase of roughly 22% and above the consensus estimate of about $11.5 million. Gross margin rose to 71.3% from 63.8% in the prior-year quarter, driven by a higher average selling price, lower material costs, and fixed-cost leverage on higher revenue units.

The company reached adjusted EBITDA break-even, compared with a loss of $2.7 million in the same period last year. Operating loss narrowed to $1.7 million from $3.5 million. Net loss was $4.2 million, or $0.10 per share, versus $3.7 million, or $0.09 per share, a year earlier; the quarter included a non-cash charge of approximately $1.8 million related to a market adjustment on derivative liabilities, as well as interest expense associated with the Avenue Capital term loan.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Myomo, it offers a structured way to surface new opportunities across industries.

Market Reaction and Investor Sentiment

The market responded positively to the report, with Myomo shares moving higher in the session following the announcement. Investors appeared to focus on the revenue beat, the sharp gross-margin expansion, and the achievement of adjusted EBITDA break-even, rather than the headline net loss per share, which was pressured by non-cash derivative-related charges. The narrowed full-year guidance, now at the top of the prior range, reinforced confidence that the company's operating leverage story remains intact heading into the fourth quarter.

Forward Outlook and Key Factors to Monitor

Management narrowed its full-year 2026 revenue guidance to $46 million to $47 million, signaling confidence in the remainder of the year. The company also expects a modest sequential increase in gross margin in the fourth quarter, reflecting the benefit of manufacturing cost-reduction initiatives.

Investors should watch operating expenses, which management expects to rise modestly in the fourth quarter due to one-time costs tied to a leadership transition and higher headcount supporting the MyoConnect program. Myomo reiterated its objective of limiting full-year operating-expense growth to half the rate of revenue growth.

Cash management remains a key theme. The company expects total cash burn in the second half of 2026 to stay below $2 million, including less than $500,000 in the fourth quarter. Other factors to monitor include pipeline growth, referral conversion, and whether the efficiency improvements in direct-to-patient lead generation continue to support order volume into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations